Several clinical and preclinical oncology developments have emerged: Summit Therapeutics reports overall survival benefit with bispecific PD-1/VEGF antibody ivonescimab in NSCLC; Remegen and Vor Bio notch phase III success for telitacicept in IgA nephropathy; and Bioxcel Therapeutics nears supplemental NDA for schizophrenia and bipolar treatment Igalmi for home use. These advancements signal progress in targeted cancer therapies and symptom management.